Establishment Labs Holdings Inc. (NASDAQ:ESTA) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) have received a consensus recommendation of “Moderate Buy” from the eight research firms that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $68.2857.

A number of equities research analysts recently issued reports on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Establishment Labs in a research note on Wednesday, November 19th. Wall Street Zen raised shares of Establishment Labs from a “sell” rating to a “hold” rating in a report on Sunday, October 19th. Citigroup reissued a “neutral” rating on shares of Establishment Labs in a research note on Tuesday, October 7th. Needham & Company LLC raised their price target on shares of Establishment Labs from $48.00 to $70.00 and gave the company a “buy” rating in a research note on Thursday, November 6th. Finally, Canaccord Genuity Group lifted their price objective on Establishment Labs from $60.00 to $72.00 and gave the stock a “buy” rating in a report on Thursday, November 6th.

Institutional Trading of Establishment Labs

Several large investors have recently made changes to their positions in ESTA. CenterBook Partners LP purchased a new position in Establishment Labs in the 2nd quarter valued at $16,204,000. Viking Global Investors LP acquired a new stake in shares of Establishment Labs in the second quarter valued at about $14,669,000. First Light Asset Management LLC purchased a new position in shares of Establishment Labs in the first quarter worth about $13,746,000. Nuveen LLC purchased a new position in shares of Establishment Labs in the first quarter worth about $13,054,000. Finally, Bamco Inc. NY boosted its position in Establishment Labs by 30.2% during the third quarter. Bamco Inc. NY now owns 1,181,824 shares of the company’s stock worth $48,443,000 after acquiring an additional 274,287 shares during the last quarter. 72.91% of the stock is currently owned by hedge funds and other institutional investors.

Establishment Labs Price Performance

NASDAQ:ESTA opened at $69.14 on Tuesday. Establishment Labs has a 52 week low of $26.56 and a 52 week high of $70.95. The company has a quick ratio of 2.10, a current ratio of 3.33 and a debt-to-equity ratio of 15.06. The stock has a market capitalization of $2.01 billion, a PE ratio of -24.34 and a beta of 0.98. The stock’s 50-day moving average price is $50.20 and its 200-day moving average price is $43.24.

Establishment Labs (NASDAQ:ESTA) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.38) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.16. Establishment Labs had a negative return on equity of 235.45% and a negative net margin of 43.45%.The company had revenue of $53.78 million during the quarter, compared to analysts’ expectations of $52.28 million. During the same quarter in the prior year, the firm posted ($0.59) EPS. Establishment Labs’s quarterly revenue was up 33.8% compared to the same quarter last year. Establishment Labs has set its FY 2025 guidance at EPS. As a group, equities analysts expect that Establishment Labs will post -2.41 EPS for the current fiscal year.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.